BRAF inhibitors (BRAFi), whether used as monotherapy or in combination with MEK inhibitors (MEKi), have demonstrated remarkable clinical efficacy in a substantial proportion of cancer patients, particularly those with melanoma harboring mutant BRAFV600E. This evidence concerns the gene MAP2K7 and melanoma.